SB WILL BE ONE OF A HANDFUL OF "GLOBAL MEGAPLAYERS" BY THE YEAR 2000, CEO LESCHLY PREDICTS; $2.6 BIL. POST-TRANSITION DEBT PAYOFF SEEN BY END OF 1997
Executive Summary
SmithKline Beecham will be one of only five to 10 or a "handful or two" of global pharmaceutical and healthcare management companies in existence by the year 2000, SB CEO Jan Leschly predicted at a Dec. 12 meeting with securities analysts in New York City.